Definium Therapeutics, Inc. Payments of Financing Costs
Definium Therapeutics, Inc. (DFTX) reported Payments of Financing Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-06
- Definium Therapeutics, Inc. payments of financing costs for the quarter ending 2025-12-31 was $0.00.
- Definium Therapeutics, Inc. payments of financing costs for the quarter ending 2025-09-30 was $0.00.
- Definium Therapeutics, Inc. payments of financing costs for the quarter ending 2025-06-30 was $447.00K.
- Definium Therapeutics, Inc. payments of financing costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Definium Therapeutics, Inc. payments of financing costs for fiscal 2025 was $447.00K, a 249.22% increase from fiscal 2024.
- Definium Therapeutics, Inc. payments of financing costs for fiscal 2024 was $128.00K, a 84.83% decline from fiscal 2023.
- Definium Therapeutics, Inc. payments of financing costs for fiscal 2023 was $844.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $447.00K derived: sum of 3 quarters · filed 2026-08-06 | $447.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $447.00K derived: sum of 2 quarters · filed 2026-08-06 | $447.00K 10-Q · filed 2025-11-06 | $447.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $447.00K 10-Q · filed 2026-08-06 | $447.00K derived: sum of 3 quarters · filed 2026-08-06 | $447.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $128.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $128.00K 10-Q · filed 2025-11-06 | $170.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $128.00K 10-Q · filed 2025-07-31 | $170.00K derived: sum of 3 quarters · filed 2025-07-31 | |
| 2024-03-31 | $128.00K 10-Q · filed 2025-05-08 | $170.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $844.00K 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $802.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |